Revvity IL-1 (human) LANCE Ultra TR-FRET Detection Kit, 10,000 Assay Points

The LANCE Ultra Human IL-1β Detection Kit is designed for detection and quantitation of human interleuukin-1β in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

The 500 point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample). The 10,000 point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample).

• No-wash steps, no separation steps
• TR-FRET technology
• Sensitive detection
• High reproducibility
• Faster time-to-results
• Easy automation
• 96-well, 384-well, and 1536-well formats

LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight^™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

IL1α and IL1ß are central players of the immune response, displaying roles in inflammation both at local and systemic levels. Despite they seem to display very similar functions, these proteins are encoded by two independent genes sharing only ~30% identity. IL1ß is synthesized as a 31 kDa precursor that is cleaved by Caspase-1 (ICE) into the active 17 kDa form, and eventually released into the extracellular space. Its production has been reported in many cell types including brain and, importantly, monocytic and periferal blood mononuclear cells. After binding to its receptor, IL-1RI, IL1ß triggers a cascade of kinase signaling pathways that lead to the activation of transcription factors like NFκB and AP-1, eventually activating the expression of genes such as MIP-2 and C-reactive protein.